Switch From Remicade to Newer Biosimilar Safe for Sarcoidosis, Study Finds

Switch From Remicade to Newer Biosimilar Safe for Sarcoidosis, Study Finds

294317

Switch From Remicade to Newer Biosimilar Safe for Sarcoidosis, Study Finds

People with severe and difficult-to-treat sarcoidosis can safely switch from Remicade (infliximab) or its biosimilar Inflectra, to another biosimilar called Flixabi and maintain similar clinical benefits, a study reports. Six months after switching, none of these patients had stopped using Flixabi or showed a worsening in lung function, but better physical abilities and disease activity scores, results showed. The study, “Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients,” was published in the journal Cells.…

You must be logged in to read/download the full post.